Document:

EX-4.18

Exhibit 4.18

ADDENDUM NO. 1

DATED
21ST OCTOBER, 2008

TO THE

SERVICES AGREEMENT

DATED
15TH MAY, 2008

(the “Agreement”)

between

OCEANFREIGHT INC.

of Majuro, Marshall Islands, lawfully represented (hereinafter sometimes the Owner)

and

CARDIFF MARINE INC.

of Monrovia, Liberia, lawfully represented (hereinafter sometimes “CARDIFF”)

Whereas the Owner has been engaged through subsidiaries in the ownership
and operation of cargo vessels trading worldwide.

Whereas, the Company has entered into a Services Agreement dated May 15th, 2008 with CARDIFF
whereby CARDIFF provides certain services to the Company in consideration of the fees set
forth in the subject Services Agreement; and

Whereas, the Financing Fee stipulated in Clause 1.4 of the Services Agreement dated May
15th, 2008 is proposed to be amended to have retroactive effect as of January 1st, 2008; and

Whereas, it is proposed that the Services Agreement be amended to include any costs incurred
by CARDIFF for inspection of vessels for possible purchase, which includes costs for any
visits by superintendents for inspection of an identified vessel for purchase, and that the
fee payable to CARDIFF shall be €500 per day plus expenses effective October 1st, 2008

Whereas it is deemed advisable by both parties that the Service Agreement be amended as
above

IT IS HEREBY AGREED AS FOLLOWS

That Clause 1.4 of the Services Agreement dated May 15th, 2008 be amended to provide that
the Financing Fee related to identifying, sourcing,

1

 

negotiating
and arranging new loan and credit facilities with lenders/financial institutions and
negotiating and arranging for interest rate swap agreements, foreign currency contracts and forward
exchange contracts, shall have retroactive effect as of January 1st, 2008 in order to provide
compensation for services already rendered without any payment

That the Services Agreement be amended to include any costs incurred by Cardiff for inspection of
vessels for possible purchase, which includes costs for any visits by superintendents for
inspection of an identified vessel for purchase, and that the fee payable to Cardiff shall be €500
per day plus expenses effective October 1st, 2008

All other terms and conditions of the Addendum Agreement dated 15th May, 2008 remain unaltered and
in full force and effect, save as may have been amended by the parties, such as with regard to a
the fees payable as above

Signed this 21st day of October 2008

	 	 	 	 	 	 	 	 	 	 	 
	/s/
Michael Gregos

	 	 
	 	/s/
Charalampos Alivizatos

	 	 
	 	 	 	 	 	 	 
	ON BEHALF OF THE OWNER	 	 	 	ON BEHALF OF CARDIFF	 	 
	 
	 	 	 	 	 	 	 	 	 	 
	By:

	Michael Gregos	 	 	 	By:
	 	Charalampos Alivizatos	 	 
	Title:

	 	Chief Operating Officer
	 	 	 	Title:
	 	Legal Representative	 	 

2EX-4.19

Exhibit
4.19

ADDENDUM AGREEMENT NO. 2

(the “Addendum Agreement”)

TO THE SERVICES AGREEMENT DATED 15TH MAY, 2008

between

OCEANFREIGHT INC.

of Majuro, Marshall Islands, lawfully represented (hereinafter sometimes the Owner)

and

Cardiff Marine Inc.

of Monrovia, Liberia, lawfully represented (hereinafter sometimes
“CARDIFF”)

Whereas the Owners have been engaged in the ownership and operation of cargo vessels trading
worldwide.

Whereas the Owner and CARDIFF as Service Provider have entered into a services agreement dated 15th
May, 2008 as amended on October 21st, 2008

IT IS HEREBY AGREED AS FOLLOWS:

That the Euro equivalent of 90 days the Manager’s Supervision Fee as specified in Clause 2.3 of the
Services Agreement (the “Security”) will be paid to CARDIFF in cash as security for the due,
punctual, proper and correct performance by the Owners of their obligations under the Services
Agreements, such payment to be made to CARDIFF upon written demand by CARDIFF to a bank account as
designated by the CARDIFF

That the Security to be paid by OceanFreight Inc. to CARDIFF with respects to the Manager’s
Supervision Fee shall €72.000 in cash (€100 per day x 8 Vessels x 90 days)

That upon the valid effective termination of the Services Agreement CARDIFF shall only be required
to return the Security amount or any portion thereof, if the amounts due to CARDIFF pursuant with
the obligations set forth in the Services Agreement and their addenda is less than the Security
amount paid as per above, it being understood that in any event of default from the part of the
Owner, the Security is forfeited in favor of CARDIFF without prejudice to any rights which CARDIFF
may have against the Owner in law or in equity

That the Security amount shall be non-refundable by CARDIFF in the event of: (i) a Change of
Control of OceanFreight Inc. and (ii) any public disclosure that OceanFreight Inc is in default of
any of its agreements including but not limited to Loan Agreements and Charter Party Agreements and
such default impairs

 

 

the Company’s ability to continue its operations. Change of Control shall have the same term and
meaning as set forth in the Services Agreement.

All other terms and conditions of the Services Agreement and the Addendum Agreement dated
21st October, 2008 remain unaltered and in full force and effect, save as may have been
amended by the parties, such as with regard to Security payable as above

[SIGNATURE
PAGE FOLLOWS]

 

 

Signed
this 14th day of January 2009.

	 	 	 	 	 
	 
	 	 	 	 
	/s/ Michael Gregos	 	 
	 	 	 
	ON BEHALF OF OCEANFREIGHT INC.	 	 
	 
	 	 	 	 
	By:

	 	Michael Gregos	 	 
	Title:

	 	COO	 	 
	 
	 	 	 	 
	/s/ Charalampos Alivizatos	 	 
	 	 	 
	ON BEHALF OF CARDIFF MARINE INC.	 	 
	 
	 	 	 	 
	By:

	 	Charalampos Alivizatos	 	 
	Title:

	 	Legal RepresentativeEX-10.44

    EXHIBIT 10.44

 

    AMENDMENT
    #1 TO THE

    CLINICAL TRIAL AGREEMENT BETWEEN

    VION PHARMACEUTICALS, INC. AND THE

    DIVISION OF CANCER TREATMENT AND DIAGNOSIS, NCI

    DATED MARCH 2, 2006

 

    The purpose of this amendment (“Amendment”), effective
    as of the last date signed below (“Effective Date”),
    is to change certain terms of the above referenced Clinical
    Trials Agreement (CTA) (“Agreement”). These changes
    are reflected below and except for these changes, all other
    provisions remain in full force and effect. Two
    (2) originals of this amendment are provided for execution;
    one is to remain with the National Cancer Institute, and the
    second is to remain with Vion Pharmaceuticals.

 

		
	
    1.  
	
    Expiration
    Date

 

    The CTA shall be amended to extend the term for conducting
    clinical studies with this Agent for a period of two
    (2) years. The date of expiration of this CTA is now
    January 9, 2008.

 

		
	
    2.  
	
    Article 1.
    Definitions

 

    “CTIS” means Capital Technology Information Service.

 

		
	
    3.  
	
    Article 6.
    Drug Information and Supply

 

    Article 6 is hereby amended as follows:

 

    The contact person for DCTD will be Mr. Charles Hall,
    Chief, Pharmaceutical Management Branch (Telephone Number
    301-496-5725).

 

    Add the following paragraph:

 

    Collaborator agrees to provide to the Pharmaceutical Management
    Branch (PMB) the Clinical Investigator’s Brochure (IB) for
    Agent and all subsequent revisions/editions. In addition to
    being filed to the CTEP IND, the IB will be on file in the PMB
    and will be distributed to all investigators participating on a
    clinical trial using the agent. For NCI trials using agent
    manufactured by NCI, PMB will attach a cover sheet to the IB
    clearly indicating the trial is sponsored by NCI and the agent
    is supplied by the NCI. All distribution will be accompanied by
    a statement about the confidentiality of the document and it is
    anticipated that distribution will be electronic. All electronic
    distribution will be done using Adobe Acrobat. Any IB received
    by the PMB that is not in this format will be converted before
    distribution. Hard copy IBs should be sent to IB Coordinator,
    Pharmaceutical Management Branch, CTEP, DCTD, NCI, 6130
    Executive Blvd, Room 7149, Rockville, MD 20852. Electronic
    versions should be emailed to the IB Coordinator at
    IBCoordinator@mail.nih.gov.

 

		
	
    4.  
	
    Article 7.
    Data Rights

 

    Article 7 is hereby amended to add the following paragraph
    to the end of the Article:

 

    DCTD will not execute a Funding Agreement for clinical trials
    for development of Agent unless the institution agrees to
    provide information to Collaborator in accord with applicable
    Federal regulations, including the Standards for Privacy of
    Individually Identifiable Health Information set forth in
    45 C.F.R. Part 164. DCTD shall advise all institutions
    conducting NCI-sponsored clinical trials that they must comply
    with all applicable federal regulations for the protection of
    human subjects, including the Privacy Rule.

 

		
	
    5.  
	
    Add the
    following Article 23:

 

    Article 23.  Monitoring

    

    90

 

    CTEP/DCTD utilizes the contract services of two companies (CTMS)
    for assistance in the monitoring of DCTD-sponsored clinical
    trials. Collaborator will be responsible for making arrangements
    directly with the appropriate DCTD contractors to receive
    reports from DCTD-sponsored trials. This will include quarterly
    reports, adverse event reports and summary reports. Each CTMS
    will be reimbursed by Collaborator for the cost of reformatting
    (if any) and reproduction of the data. CTIS, the contractor for
    most Phase 2 and 3 studies will provide these reports
    electronically in a format compatible with Collaborator’s
    database at a cost of $2000 per year, payable directly to CTIS.
    Theradex, the CTMS NCI Phase 1 contractor, will also provide
    reports directly to Collaborator in a format negotiated by
    Collaborator and Theradex. Contact information for each
    contractor will be provided as needed.

 

    Any additional requests which involve the collection of more
    than summarized data provided annually will be at the expense of
    Collaborator. Should DCTD conduct an audit to confirm the
    anti-tumor activity of a treatment regimen using Agent,
    Collaborator is encouraged to attend and participate in the data
    review. Since data will be collected under the NCI IND, should
    Collaborator choose to contact an investigator to collect or
    review data, Collaborator must first contact the Regulatory
    Affairs Branch, DCTD for prior approval, which approval shall
    not be unreasonably withheld. Upon approval of
    Collaborator’s request, the Regulatory Affairs Branch will
    notify the investigator(s) of Collaborator’s request and
    instruct the investigator(s) to provide full access to the
    requested data. Collaborator will reimburse the investigator(s)
    for any and all costs associated with fulfilling
    Collaborator’s request.

 

    AGREED TO
    AND ACCEPTED BY:

 

	 	 	 
	

    For the National Cancer Institute:

	
 
	
 

	
 
	
 
	
 

	

    /s/  James
    Doroshow

	
 
	
    February 13, 2006

	
    

	
 
	
    

	

    James Doroshow, M.D., FACP

	
 
	
    Date

	

    Director, Division of Cancer Treatment and Diagnosis

	
 
	
 

	
 
	
 
	
 

	

    For Vion Pharmaceuticals:

	
 
	
 

	
 
	
 
	
 

	

    /s/  Ann
    Cahill

	
 
	
    March 2, 2006

	
    

	
 
	
    

	

    Ann Cahill PA-C

	
 
	
    Date

	

    Vice President, Clinical Development

	
 
	
 

    

    91

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00156-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00156-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00156-of-00352.parquet"}]]